Company news

AgomAb Therapeutics NV news in 2026

AgomAb Therapeutics NV's news releases, calls and decks from 2026, newest first.

View company

Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease

October 13, 2026

Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation

October 8, 2026

Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease

October 1, 2026

Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study

September 14, 2026

Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors

September 11, 2026

Agomab to Participate in Upcoming Investor Conferences

September 3, 2026

Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors

August 10, 2026

Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook

August 6, 2026

Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease

June 23, 2026

Agomab Announces Results of Annual General Meeting

May 27, 2026

Agomab to Participate in Upcoming Conferences

May 14, 2026

Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

April 23, 2026

Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis

March 26, 2026

Agomab Announces Closing of Initial Public Offering

February 9, 2026

Agomab Announces Pricing of Initial Public Offering

February 5, 2026

Decks in 2026